<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Armata Pharmaceuticals, Inc. — News on 6ix</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc</link>
<description>Latest news and press releases for Armata Pharmaceuticals, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/armata-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7358a51cc36e47532e1f9.webp</url>
<title>Armata Pharmaceuticals, Inc.</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc</link>
</image>
<item>
<title>Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-appointment-of-biopharmaceutical-commercial-executive-daniel-b-gilmer-phd-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-appointment-of-biopharmaceutical-commercial-executive-daniel-b-gilmer-phd-to-its-board-of-directors</guid>
<pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Daniel B. Gilmer, Ph.D. has joined the Company's Board of Directors, effective April 24, 2026. Dr. Gilmer has served as Senior Director, Commercial Quality U.S. Team Lead at Pfizer</description>
</item>
<item>
<title>Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 25 Mar 2026 20:05:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2025.</description>
</item>
<item>
<title>Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-delays-announcement-of-fourth-quarter-and-full-year-2025-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-delays-announcement-of-fourth-quarter-and-full-year-2025-results-and-provides-corporate-update</guid>
<pubDate>Thu, 19 Mar 2026 11:00:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it will delay the announcement of its financial results for its fourth quarter and full-year ended December 31, 2025, and provided a corporate update.</description>
</item>
<item>
<title>Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-receives-fda-qualified-infectious-disease-product-qidp-designation-for-ap-sa02</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-receives-fda-qualified-infectious-disease-product-qidp-designation-for-ap-sa02</guid>
<pubDate>Mon, 23 Feb 2026 12:00:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted AP-SA02, the Company's Staphylococcus aureus ("S. aureus") multi-phage product candidate, for intravenous use as a Qua</description>
</item>
<item>
<title>/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/c-o-r-r-e-c-t-i-o-n-armata-pharmaceuticals-inc</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/c-o-r-r-e-c-t-i-o-n-armata-pharmaceuticals-inc</guid>
<pubDate>Tue, 13 Jan 2026 12:42:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced the conclusion of an End-of-Phase 2 ("EOP2") written response from the U.S. Food and Drug Administration ("FDA") and plans to advance the Company's intravenously-administered Staphyloco</description>
</item>
<item>
<title>Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-key-opinion-leader-webinar-on-s-aureus-bacteremia-and-ap-sa02-hosted-by-jones-research-on-november-25th-at-1000am-est</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-key-opinion-leader-webinar-on-s-aureus-bacteremia-and-ap-sa02-hosted-by-jones-research-on-november-25th-at-1000am-est</guid>
<pubDate>Tue, 18 Nov 2025 12:00:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will be featured in a key opinion leader (KOL) webinar, "Redefining SoC in Complicated Staph. aureus Bacteremia to Unlock a Real Opportunity" on November 25th, 2025 at 10:00</description>
</item>
<item>
<title>Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-third-quarter-2025-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-third-quarter-2025-results-and-provides-corporate-update</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2025, and provided a corporate update.</description>
</item>
<item>
<title>Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-formal-commissioning-of-state-of-the-art-cgmp-phage-manufacturing-facility-in-los-angeles-california</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-formal-commissioning-of-state-of-the-art-cgmp-phage-manufacturing-facility-in-los-angeles-california</guid>
<pubDate>Mon, 10 Nov 2025 12:00:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its state-of-the-art current Good Manufacturing Practice ("cGMP") manufacturing facility in Los Angeles, California, has been formally commissioned. As part of the commissioning process</description>
</item>
<item>
<title>Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-highlights-positive-results-from-phase-2a-disarm-study-of-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-in-late-breaking-oral-presentation-at-idweek-2025tm</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-highlights-positive-results-from-phase-2a-disarm-study-of-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-in-late-breaking-oral-presentation-at-idweek-2025tm</guid>
<pubDate>Wed, 22 Oct 2025 15:10:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today highlighted positive results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment for complicated Staphylococcus aureus ("S. aureus") bacteremia ("SAB") in a late-brea</description>
</item>
<item>
<title>Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025tm</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-to-present-late-breaking-clinical-data-highlighting-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-at-idweek-2025tm</guid>
<pubDate>Tue, 14 Oct 2025 11:00:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced it will be presenting late-breaking Phase 2a clinical data on its Staphylococcus aureus bacteriophage cocktail, AP-SA02, at IDWeek 2025™, which is being held October 19-22, 2025, in Atlanta,</description>
</item>
<item>
<title>Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-structural-biology-publication-in-the-journal-of-molecular-biology</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-structural-biology-publication-in-the-journal-of-molecular-biology</guid>
<pubDate>Mon, 08 Sep 2025 11:00:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology (JMB).</description>
</item>
<item>
<title>Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held in New Yor</description>
</item>
<item>
<title>Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-second-quarter-2025-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-second-quarter-2025-results-and-provides-corporate-update</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2025, and provided a corporate update.</description>
</item>
<item>
<title>Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-positive-topline-data-from-the-phase-1b2a-disarm-study-of-intravenously-administered-ap-sa02-in-complicated-staphylococcus-aureus-bacteremia</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-positive-topline-data-from-the-phase-1b2a-disarm-study-of-intravenously-administered-ap-sa02-in-complicated-staphylococcus-aureus-bacteremia</guid>
<pubDate>Mon, 19 May 2025 11:00:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced positive topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous ("IV") administered multi-phage therapeutic for the treatment of Staphylococcus aureus</description>
</item>
<item>
<title>Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-first-quarter-2025-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-announces-first-quarter-2025-results-and-provides-corporate-update</guid>
<pubDate>Wed, 14 May 2025 20:05:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2025, and provided a corporate update.</description>
</item>
<item>
<title>Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02</title>
<link>https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-receives-dollar465-million-of-additional-non-dilutive-award-funding-from-the-us-department-of-defense-to-support-ongoing-disarm-clinical-trial-of-ap-sa02</link>
<guid isPermaLink="true">https://6ix.com/company/armata-pharmaceuticals-inc/news/armata-pharmaceuticals-receives-dollar465-million-of-additional-non-dilutive-award-funding-from-the-us-department-of-defense-to-support-ongoing-disarm-clinical-trial-of-ap-sa02</guid>
<pubDate>Thu, 01 May 2025 11:00:00 GMT</pubDate>
<description>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $4.65 million of non-dilutive funding pursuant to a previously announced Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium</description>
</item>
</channel>
</rss>